Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 13.2% – Here’s Why

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price was up 13.2% during trading on Monday . The stock traded as high as $8.06 and last traded at $8.04. Approximately 4,246,413 shares were traded during trading, a decline of 25% from the average daily volume of 5,661,439 shares. The stock had previously closed at $7.10.

Analyst Upgrades and Downgrades

RXRX has been the topic of several research reports. Jefferies Financial Group decreased their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Price Performance

The firm’s 50 day moving average price is $6.61 and its two-hundred day moving average price is $7.62. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the previous year, the company posted ($0.43) earnings per share. The company’s revenue was up 147.6% on a year-over-year basis. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $7.56, for a total transaction of $45,360.00. Following the completion of the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at $3,939,803.28. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,939,803.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total value of $92,550.00. Following the completion of the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at approximately $8,500,754.52. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 156,682 shares of company stock valued at $1,012,618. 15.75% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $25,000. Farther Finance Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares in the last quarter. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after purchasing an additional 6,036 shares during the last quarter. KBC Group NV raised its holdings in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank lifted its position in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.